Epristeride

Epristeride

Systematic (IUPAC) name
17-(tert-butylcarbamoyl)androsta-3,5-diene-3-carboxylic acid
Clinical data
Routes of administration	Oral
Legal status	Investigational New Drug, not FDA approved
Pharmacokinetic data
Bioavailability	93%[1]
Biological half-life	26 hours[1]
Identifiers
CAS Number	119169-78-7
ATC code	None
PubChem	CID 68741
ChemSpider	10625794
UNII	39517A04PS
ChEMBL	CHEMBL290823
Chemical data
Formula	C25H37NO3
Molar mass	399.566 g/mol
SMILES CC(C)(C)NC(=O)C1CCC2C3C\C=C4\C=C(/CCC4(C)C3CCC12C)C(O)=O
InChI InChI=1S/C25H37NO3/c1-23(2,3)26-21(27)20-9-8-18-17-7-6-16-14-15(22(28)29)10-12-24(16,4)19(17)11-13-25(18,20)5/h6,14,17-20H,7-13H2,1-5H3,(H,26,27)(H,28,29) Key:VAPSMQAHNAZRKC-UHFFFAOYSA-N

Epristeride (SKF-105,657, ONO-9302) is a selective, transition state, non-competitive inhibitor of the type II isoform of the enzyme 5α-reductase,^[2][3] similarly to finasteride and turosteride. It was under development for the treatment of benign prostatic hyperplasia and acne vulgaris by SmithKline Beecham (now GlaxoSmithKline), and reached phase III clinical trials in the United States, United Kingdom, and Japan,^[2] but ultimately was never marketed.

See also

• 5α-reductase inhibitor

References

1. Benincosa LJ, Audet PR, Lundberg D, Zariffa N, Jorkasky DK (April 1996). "Pharmacokinetics and absolute bioavailability of epristeride in healthy male subjects". Biopharmaceutics & Drug Disposition 17 (3): 249–58. doi:10.1002/(SICI)1099-081X(199604)17:3<249::AID-BDD952>3.0.CO;2-E. PMID 8983399.
2. Hedge SS (May 1998). "Epristeride SmithKline Beecham". IDrugs : the Investigational Drugs Journal 1 (1): 152–7. PMID 18465521.
3. Berthaut I, Mestayer C, Portois MC, Cussenot O, Mowszowicz I (August 1997). "Pharmacological and molecular evidence for the expression of the two steroid 5 alpha-reductase isozymes in normal and hyperplastic human prostatic cells in culture". The Prostate 32 (3): 155–63. doi:10.1002/(SICI)1097-0045(19970801)32:3<155::AID-PROS1>3.0.CO;2-K. PMID 9254894.